Vivos Therapeutics Inc (VVOS)

Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity

LITTLETON, Colo., June 22, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”...

Form 8-K - Current report

Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering

LITTLETON, Colo., June 11, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”...

Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients

LITTLETON, Colo., June 10, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company...

Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026

LITTLETON, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’...

Form 8-K - Current report

Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing

LITTLETON, Colo., June 05, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update

Year-over-year revenue increased 70%, reflecting contribution from Vivos’ acquisition of The Sleep Center of...

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB

Form EFFECT - Notice of Effectiveness

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 8-K - Current report

Form 8-K - Current report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]